BioRestorative Therapies, Inc. Logo

BioRestorative Therapies, Inc.

Develops adult stem cell therapies for degenerative disc and metabolic disorders.

BRTX | US

Overview

Corporate Details

ISIN(s):
US0906556065
LEI:
Country:
United States of America
Address:
40 MARCUS DRIVE, 11747 MELVILLE

Description

BioRestorative Therapies, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicine products and cell-based therapies. The company utilizes adult stem cells to address unmet medical needs, primarily in degenerative disc disease and metabolic disorders. Its lead clinical program, BRTX-100, is an autologous stem cell therapy for chronic lumbar disc disease currently in a Phase 2 clinical trial. Another development program, ThermoStem, uses brown adipose-derived stem cells to target metabolic conditions. In addition to its therapeutic pipeline, the company has a BioCosmeceutical platform that develops biologics based on secretome technology, including exosomes and growth factors, for aesthetic medicine applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-19 16:06 English ZIP 8.1 KB
2025-12-12 23:11
PROSPECTUS RE 508,592 SHARES OF COMMON STOCK
English ZIP 58.2 KB
2025-12-11 06:15 English ZIP 5.2 KB
2025-11-18 22:48
S-8
English ZIP 60.9 KB
2025-11-18 22:45
S-1
English ZIP 167.3 KB
2025-11-12 23:00
10-Q
English ZIP 932.1 KB
2025-11-12 22:11
THIRD QUARTER 2025 FINANCIAL RESULTS
English ZIP 5.3 MB
2025-10-20 14:18 English ZIP 8.1 KB
2025-10-20 14:02 English ZIP 7.8 KB
2025-10-09 18:50 English ZIP 8.3 KB
2025-10-08 23:10
8-K
English ZIP 386.9 KB
2025-10-08 22:25
424B5
English ZIP 109.8 KB
2025-10-06 17:55
424B5
English ZIP 15.5 KB
2025-09-25 17:49
ANNUAL MEETING VOTE
English ZIP 61.9 KB
2025-08-14 23:08
PRESENTATION MATERIALS
English ZIP 15.3 MB

Automate Your Workflow. Get a real-time feed of all BioRestorative Therapies, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioRestorative Therapies, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioRestorative Therapies, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD
Gubra A/S Logo
Biotech and CRO focused on peptide drugs for metabolic and fibrotic diseases.
Denmark
GUBRA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.